ROYAL BANK OF CANADA - SYROS PHARMACEUTICALS INC ownership

Quarter-by-quarter ownership
ROYAL BANK OF CANADA ownership history of SYROS PHARMACEUTICALS INC
ValueSharesWeighting
Q3 2023$4,000
-20.0%
942
-37.2%
0.00%
Q2 2023$5,000
+400.0%
1,501
+495.6%
0.00%
Q1 2023$1,000252
+3500.0%
0.00%
Q4 2022$07
-80.6%
0.00%
Q3 2022$0360.00%
Other shareholders
SYROS PHARMACEUTICALS INC shareholders Q4 2023
NameSharesValueWeighting ↓
Ally Bridge Group (NY) LLC 868,403$3,117,5673.03%
Bain Capital Life Sciences Investors, LLC 2,124,694$7,6280.85%
Samsara BioCapital, LLC 881,450$3,164,4060.68%
Altium Capital Management LP 315,070$1,131,1010.58%
Omega Fund Management, LLC 251,270$902,0590.30%
Artal Group S.A. 1,463,829$5,2550.29%
DAFNA Capital Management LLC 265,878$954,5020.27%
CVI Holdings, LLC 425,500$1,527,5450.20%
Flagship Pioneering Inc. 993,848$3,567,9140.11%
Avidity Partners Management LP 900,000$3,231,0000.07%
View complete list of SYROS PHARMACEUTICALS INC shareholders